RetaCalc
Protocol library
SingleInvestigationalEarly HumanLow confidenceSourced

DSIP

A small neuropeptide investigated in older and heterogeneous sleep experiments. The literature does not support a current standard administration protocol.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Community GuideSubcutaneous in guideDaily
Third-party educational schedule for a 5 mg research vial

100 mcg daily in week 1, 150 mcg in week 2, 200 mcg in week 3 and 250-300 mcg daily in weeks 4-8

This schedule is not reproduced by a modern controlled human trial. Historical DSIP studies were small and heterogeneous, so confidence remains very low.

View source

Evidence summary

A small neuropeptide investigated in older and heterogeneous sleep experiments. The literature does not support a current standard administration protocol.

Protocol basis

The evidence level reflects historical human exposure, but the absence of a coherent replicated schedule keeps confidence low.

What remains uncertain

A validated indication, modern controlled efficacy, optimal route and product equivalence are not established.

Warnings and contraindications

Human studies are old, small and methodologically heterogeneous.
Sleep effects were inconsistent and do not establish a routine protocol.
Modern formulation, pharmacokinetic and long-term safety data are lacking.